At X-Chem, DEL screen data isn’t just used for Hit ID
At X-Chem, DEL isn’t just a screening tool. It’s the engine that powers Chemomics: a discovery model built to generate not only hits, but insight. Chemomics transforms the full DEL dataset into predictive SAR, structure–function insight, and decision-ready direction at the start of your program.
What Sets X-Chem DELs Apart
- Proprietary DELs with deep chemical diversity, including lead-like and covalent collections
- Unmatched selection science, optimized for novel modalities and complex targets
- AI/ML-driven hit prediction and structure-function mapping
- Integrated follow-up chemistry to move from hits to leads faster
- Proven success across 30+ target classes and 85+ licensing programs
Approaches that Meet You Where You Are
Whether you’re a startup seeking de-risked discovery, a mid-size biotech validating a new modality, or a global pharma expanding a portfolio, X-Chem’s DEL solutions scale with your needs:
- Start with DELability, and progress into DELflex or DELcore with full confidence.
- Integrate HITMiner to identify higher-quality hits and avoid downstream attrition.
- Use covalent libraries and proprietary screening to unlock irreversible mechanisms of action.
- Access medicinal chemistry follow-up for faster hit-to-lead transitions.
DEL Program Needs and Solutions
Whether you need full-service discovery or flexible screening support, our DEL Hit-ID business models are designed to meet you where you are and move your program forward.
Rapid, full-service discovery with expert oversight
DELcore
Our most comprehensive platform. Ideal for partners seeking a deeply integrated, target-exclusive discovery relationship. Includes access to our largest DEL collection, expert reagent optimization, and full hit-to-lead support.Flexible, cost-effective access to powerful DEL screens
DELFlex
Designed for biotechs and early-stage teams. Includes bundled access to high-performing DEL sets with transparent pricing, full data access, and optional follow-on chemistry.Evaluate a target’s DEL screen suitability before full investment
DELability
Feasibility screens with real data on target tractability. A fast, low-cost way to validate target readiness and prioritize high-value efforts.Screen for covalent inhibitors against challenging targets
Covalent Irreversible
Industry’s leading covalent DEL platform. Electrophilic libraries optimized to identify irreversible inhibitors with potent, selective profiles.Accelerate hit-finding with AI/ML-enhanced insights
HITMiner
Combines DEL selection data with proprietary ML models for high-confidence hit proposals in 3–4 weeks. Ideal for time-sensitive, high-risk programs.Instantly enhance your in-house DEL capabilities
ReadiDEL
Ready-to-use off-the-shelf DELs from X-Chem’s elite collection. Includes tag-chemistry keys for internal decoding. No synthesis needed.Transforming Drug Discovery Across Target Classes
From challenging proteins to nucleic acids and viral pathogens, our platform unlocks insights that make once-unattainable therapies possible.
- Target complex disease mechanisms: Advance treatments through modalities like targeted protein degradation, protein–protein interaction modulation, and RNA-targeted therapeutics—addressing hard-to-drug targets once considered out of reach.
- Expand therapeutic modalities: Discover starting points for covalent inhibitors, molecular glues, GPCR modulators, and more.
- Modulate epigenetic pathways: Use small molecules to regulate factors implicated in cancer, neurodegeneration, and genetic diseases.
- Target immune and viral pathways: Explore immune checkpoint modulation, viral enzymes, and host–virus interactions.
- Impact cell signaling and receptors: Modulate receptors, kinases, and ion channels to address neurological, cardiovascular, and metabolic disorders.
Custom Libraries Built Around Your Chemistry
If you have proprietary compounds, we can transform them into a fully unique DEL built for your goals. X-Chem handles the design, synthesis, and encoding—all under full confidentiality.
- Reserved Access: Library and resultant data secured for your program alone
- Fully Confidential: Protected under strict IP terms
- Expertly Built: Powered by X-Chem’s DEL chemistry and screening expertise
- Strategically Valuable: Tailored to support novel scaffolds, modalities, or mechanisms
Custom libraries are ideal for pharma teams with internal building blocks, med chem innovation, or platform differentiation goals.
Leverage proprietary chemistry and unique scaffolds
Custom Libraries
Build exclusive DELs with your building blocks. Maintain IP ownership while accessing X-Chem’s synthesis expertise and platform power.Built by the Pioneers. Trusted by the Industry.
X-Chem didn’t just adopt DEL technology. We helped invent the playbook.
With over 15 years of innovation and the largest network of successful DEL-based collaborations in the world, our platform has shaped the standards others follow.
What sets our DELs apart is the integrity and richness of the data itself. Every library is designed to optimize developability, atom efficiency, and chemical diversity. Every selection is performed with multiplexed, mechanism-focused strategies that produce clearer signals and cleaner hit lists. Every dataset is validated and structured for real-world decision-making, not just publication.
That’s why our DEL data works
Whether you’re running a single screen or feeding predictive models, our data gives you the clarity, confidence, and coverage to drive discovery forward.
- Our DELs cover the widest span of chemical space, not by chasing numbers, but by focusing on BB-centric design criteria and new reaction development
- Sophisticated data analysis strategies that reduce noise and uncover meaningful SAR
- High-quality screening outputs support AI/ML, structure-function mapping, and early MOA insight
- Consistent performance across diverse modalities and challenging targets
Most DELs just screens. Ours discovers.
Why Our DELs Outperform
| Screening Attribute | X-Chem | Others |
|---|---|---|
| Library Diversity | Nearly 100 different schemes employing low cycle counts and 10’s of thousands of building blocks | High cycle counts and 100s of building blocks |
| DEL Design Philosophy | Lead-like, developable, atom-efficient | Often focused on size, not quality |
| Selection Science | Custom multiplexed, MOA-focused, optimized for novel modalities | Generic panning or single-mode |
| Output Data | Rich SAR, structure-function maps, ML-ready | Often limited to hit ID lists |
| Integration | Full hit-to-lead transition with in-house med chem | Fragmented or hand-off model |
| AI/ML Integration | HITMiner: DEL-trained ML for hit scoring and compound prioritization | Rare or retrospective AI models |
Choose the Path That Fits Your Discovery Journey
| You Are.. | Your Goal | Best X-Chem Path |
|---|---|---|
| A Biotech Preparing for Series A/B | De-risk novel target & show quick progress | DELability → DELflex | HitBuilder |
| An Academic or Platform Startup | Validate a unique modality or protein binder | DELflex or HITMiner | HitBuilder |
| A Mid-size Pharma R&D Team | Hit-finding for a new target class | DELcore or Custom DEL | HitBuilder |
| A Global Pharma Team | Scalable pipeline building | DELcore + Medicinal Chemistry Integration | LeadBuilder or CandidateBuilder |
| An In-house DEL Lab | Expand libraries without reinventing the wheel | ReadiDEL + ReadiBLOX | Platform Enablement |
From Hits to IND – Without Losing Momentum
X-Chem’s medicinal chemistry team knows our DELs inside and out. You don’t waste time onboarding or re-validating hits. You move faster from screen to series expansion, optimization, and candidate selection—with our full analytical and computational sciences toolkit at your side.
Result: More than half of our med chem projects deliver candidate-quality compounds.
Partner with the Global Leaders in DEL
X-Chem has delivered more DEL-driven clinical candidates than any other provider. Our platforms are built to produce not just data—but decisions.
DEL Track Record
We have delivered over 90 programs to our partners and clients, comprising over 1,000 novel, validated hit compounds across more than 30 different target classes. Most of these projects are actively progressed by our clients and remain confidential, but examples have been published in peer-reviewed journals.
